Lumateperone-d4

Lumateperone-d4 (ITI-007-d4) is deuterium labeled Lumateperone. Lumateperone (ITI-007) is an orally active 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone has anticancer activity and can also be used for the study of schizophrenia and bipolar depression[1][2][3].

Product Specifications

CAS Number

[2102683-55-4]

Product Name Alternative

ITI-007-d4

UNSPSC

12352005

Target

5-HT Receptor; Dopamine Receptor; Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Neuronal Signaling; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Smiles

CN1C2=C3C([C@@]4([H])[C@@](CCN(C4)CCCC(C5=CC=C(C=C5)F)=O)([H])N3C([2H])([2H])C1([2H])[2H])=CC=C2

Molecular Formula

C24H24D4FN3O

Molecular Weight

397.52

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Lumateperone|[3]Jinyuan Zhang, et al. Identification of Trovafloxacin, Ozanimod, and Ozenoxacin as Potent c-Myc G-quadruplex Stabilizers to Suppress c-Myc Transcription and Myeloma Growth. Mol Inform. 2022 Mar 30:e2200011.|[4]J Titulaer, et al. Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D1 receptor dependent mechanism. Eur Neuropsychopharmacol. 2022 Jul 22;62:22-35.